Liquidia Corporation (LQDA)
Can LQDA's Yutrepia Sustain Growth Amid Fierce PAH Competition?
Liquidia's Yutrepia is driving rapid growth, but fierce PAH competition and new pipeline therapies could challenge its momentum.
Is the Options Market Predicting a Spike in Liquidia Stock?
Investors need to pay close attention to LQDA stock based on the movements in the options market lately.
Liquidia: A Linear Launch Priced For Exponential Growth
Liquidia Corporation is rated Sell due to YUTREPIA's decelerating growth and an overextended $6B+ valuation. YUTREPIA's percentage growth is compressing, prescriber acquisition has halved, and launch-era tailwinds are fading. Future growth will require difficult community penetration and overcoming structural headwinds from patient mortality and discontinuation.
Liquidia vs. Insmed: Which Pulmonary Stock Has Better Prospects Now?
Liquidia's Yutrepia is driving strong growth, but Insmed's Brinsupri and broader pipeline could make it the better long-term pick.
Will LQDA's Differentiated PAH Approach Drive Growth?
LQDA's Yutrepia is driving rapid growth, but intensifying PAH competition could test its ability to sustain momentum.
Can Yutrepia's Strong Growth Drive Liquidia's PAH Expansion?
Liquidia's Yutrepia is gaining traction, with $300.3M in first-half sales and nearly 30% of inhaled-market revenues in Q2.
LQDA Stock Down Post Q2 Earnings Release: What Should Investors Do Now?
Liquidia's Yutrepia is fueling rapid growth, but patent litigation, competition and heavy product dependence weigh on its outlook.
LQDA Q2 Earnings Top, Strong Yutrepia Sales Fuel Top-Line Growth
Yutrepia sales fuel Liquidia's Q2 growth as revenues surge and profitability rises, while the company targets more than $1 billion in 2027 revenues.
LQDA Q2 Earnings Call Highlights YUTREPIA and $1B 2027 Revenue Path
Liquidia targets more than $1 billion in 2027 net revenues as YUTREPIA gains share and funds a broader inhaled-treprostinil pipeline.
Liquidia: YUTREPIA's Launch Opens Upside If Growth Remains And Margins Follow
YUTREPIA's commercial launch continues to scale, with Q2 product sales of $170.4 million, up 31% sequentially. Q2 largely resolved the margin concern: product gross margin remained about 93.7% despite fully costed inventory, while operating margin reached roughly 49.8%. The key debate has shifted from profitability to growth. Liquidia now needs about $210 million of quarterly revenue in Q3 and Q4 to reach the current $725 million FY2026 consensus.
Liquidia Corporation (LQDA) Q2 2026 Earnings Call Transcript
Liquidia Corporation (LQDA) Q2 2026 Earnings Call Transcript
Liquidia Q2 Earnings Call Highlights
Liquidia NASDAQ: LQDA reported second-quarter 2026 results marked by continued growth for its inhaled treprostinil product YUTREPIA, increased profitability and expanding investment in its clinical pipeline.
